PACLITAXEL (TAXOL(R)) - A REVIEW OF ITS ANTITUMOR-ACTIVITY IN CLINICAL-STUDIES - MINIREVIEW

Citation
R. Hajek et al., PACLITAXEL (TAXOL(R)) - A REVIEW OF ITS ANTITUMOR-ACTIVITY IN CLINICAL-STUDIES - MINIREVIEW, Neoplasma, 43(3), 1996, pp. 141-154
Citations number
158
Categorie Soggetti
Oncology
Journal title
ISSN journal
00282685
Volume
43
Issue
3
Year of publication
1996
Pages
141 - 154
Database
ISI
SICI code
0028-2685(1996)43:3<141:P(-ARO>2.0.ZU;2-K
Abstract
The paclitaxel represents first agent from novel class of antineoplast ic drugs-taxoids. The clinical development of paclitaxel was initially hampered by hypersensitivity reactions. Current dosage regiments with premedication reduced the incidence of these side effects to less tha n 3%. The major dose-limiting adverse effect of paclitaxel is neutrope nia Significant activities have been reported in patients with advance d ovarian, breast, non-small cell lung cancer (NSCLC) and head and nec k cancer. Combination of paclitaxel with platinum in the treatment of patients with advanced ovarian cancer has a potential to become first- line chemotherapy regimen in the treatment of this disease. Long-term. follow-up will also allow to determine the effect of the drug on pati ent survival. The promising results of this drug in the treatment of p atients with other malignancies need to be confirmed in ongoing clinic al studies.